SEC Form 4 · accession 0000899243-17-019737
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirske
Officer — See Remarks
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 7:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.43 | Aug 1, 2017 | A | 25,000 | A | — | Aug 1, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date.
Remarks
principal financial and accounting officer